Aug 11, 2021 5:30am EDT Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
Aug 03, 2021 5:30am EDT Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
Jul 22, 2021 9:35am EDT Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
Jun 29, 2021 5:30am EDT Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
Jun 03, 2021 5:30am EDT Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
Jun 02, 2021 5:30am EDT Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
May 27, 2021 4:05pm EDT Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 25, 2021 8:30am EDT Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering
May 13, 2021 4:05pm EDT Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update